Frank Himmelsbach
University of Freiburg(DE)
Publications by Year
Research Areas
DNA and Nucleic Acid Chemistry, Diabetes Treatment and Management, HER2/EGFR in Cancer Research, Biochemical and Molecular Research, Lung Cancer Treatments and Mutations
Most-Cited Works
- → BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models(2008)1,434 cited
- → Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker(2012)858 cited
- → Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors(2011)591 cited
- → 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes(2007)282 cited
- → (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors(2008)278 cited
- → The p-nitrophenylethyl (NPE) group(1984)202 cited
- → Profound and Sustained Inhibition of Platelet Aggregation by Fradafiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, and Its Orally Active Prodrug, Lefradafiban, in Men(1997)78 cited
- → Sequential C–H Arylation and Enantioselective Hydrogenation Enables Ideal Asymmetric Entry to the Indenopiperidine Core of an 11β-HSD-1 Inhibitor(2016)54 cited
- → Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats(2011)48 cited
- → Inhibition of Epidermal Growth Factor Receptor Activity by Two Pyrimidopyrimidine Derivatives(2004)43 cited